Clinical Trial Preference Study
Launched by RUSH UNIVERSITY MEDICAL CENTER · Dec 11, 2024
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
The Clinical Trial Preference Study is a research project aimed at understanding how to make clinical trials more appealing to people from diverse backgrounds who are often underrepresented in these studies. The goal is to find out what specific features of clinical trials might encourage more individuals from different racial and ethnic groups, as well as those from lower socioeconomic backgrounds, to participate. Researchers will look at preferences for things like receiving full results versus limited results, how much effort participants have to put in, whether assessments are done at home or in a clinical setting, and if the results are relevant to specific social groups or the general population.
To be eligible for this study, participants must be at least 18 years old, live in the United States, and have internet access with audio and visual capabilities. They should also be able to read and speak English. If you join the study, you'll be part of a larger group of 800 individuals who will share their thoughts on what makes a clinical trial more attractive. The information gathered will help researchers design better trials in the future, making it easier to include diverse participants and address health disparities.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Internet access with audio and visual capabilities
- • Reside within the United States
- • Read and speak English
- Exclusion Criteria:
- • Under 18 years of age
- • No internet access
- • Reside outside of the United States
- • Do not read and speak English
About Rush University Medical Center
Rush University Medical Center is a leading academic medical institution located in Chicago, Illinois, dedicated to advancing healthcare through innovative research and clinical trials. As a sponsor of numerous clinical studies, Rush focuses on translating scientific discoveries into effective treatments and improving patient outcomes across a variety of medical disciplines. With a commitment to excellence in patient care, education, and research, Rush leverages its state-of-the-art facilities and a robust network of specialists to conduct comprehensive trials that adhere to the highest ethical and regulatory standards. Through collaboration with a diverse patient population, Rush aims to enhance the understanding of diseases and develop novel therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported